Search

Your search keyword '"Psichogiou, Mina"' showing total 439 results
Start Over Author "Psichogiou, Mina"
439 results on '"Psichogiou, Mina"'

1. EAES, SAGES, and ESCP rapid guideline: bowel preparation for minimally invasive colorectal resection

Author

Antoniou, Stavros A., Huo, Bright, Tzanis, Alexander A., Koutsiouroumpa, Ourania, Mavridis, Dimitrios, Balla, Andrea, Dore, Suzanne, Kaiser, Andreas M., Koraki, Eleni, Massey, Lisa, Pellino, Gianluca, Psichogiou, Mina, Sayers, Adele E., Smart, Neil J., Sylla, Patricia, Tschudin-Sutter, Sarah, Woodfield, John C., Carrano, Francesco Maria, Ortenzi, Monica, and Morales-Conde, Salvador

Published
2023
Full Text
View/download PDF

2. Molecular epidemiology of HIV among people who inject drugs after the HIV-outbreak in Athens, Greece: Evidence for a ‘slow burn’ outbreak

Author

Kostaki, Evangelia Georgia, Roussos, Sotirios, Kefala, Anastasia Maria, Limnaios, Stefanos, Psichogiou, Mina, Papachristou, Eleni, Nikolopoulos, Georgios, Flountzi, Eleni, Friedman, Samuel R., Lagiou, Pagona, Hatzakis, Angelos, Sypsa, Vana, Magiorkinis, Gkikas, Beloukas, Apostolos, and Paraskevis, Dimitrios

Published
2024
Full Text
View/download PDF

3. High levels of all-cause mortality among people who inject drugs from 2018 to 2022

Author

Roussos, Sotirios, Angelopoulos, Theodoros, Cholongitas, Evangelos, Savvanis, Spyridon, Papadopoulos, Nikolaos, Kapatais, Andreas, Chounta, Athina, Ioannidou, Panagiota, Deutsch, Melani, Manolakopoulos, Spilios, Sevastianos, Vasileios, Papageorgiou, Maria-Vasiliki, Vlachogiannakos, Ioannis, Mela, Maria, Elefsiniotis, Ioannis, Vrakas, Spyridon, Karagiannakis, Dimitrios, Pliarchopoulou, Fani, Chaikalis, Savvas, Tsirogianni, Effrosyni, Psichogiou, Mina, Kalamitsis, Georgios, Leobilla, Foteini, Paraskevis, Dimitrios, Malliori, Meni, Goulis, Ioannis, Papatheodoridis, Georgios, Hatzakis, Angelos, and Sypsa, Vana

Published
2024
Full Text
View/download PDF

7. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Author

Akova, Murat, AlAgha, Rawan, Alangaden, George, Albrecht, Svenja J, Alexander, Barbara, Al-Obaidi, Mohanad, Ambasch, German, Armestar Rodriguez, Fernando, Azap, Alpay, Baffoe-Bonnie, Anthony, Belkhir, Leila, Ben-Ami, Ronen, Boutoille, David, Cascio, Antonio, Chai, Louis YA, Chaiwarith, Romanee, Chayakulkeeree, Methee, Chen, Sharon, Chen, Yee-Chun, Chen, Yen-Hsu, Choi, Jun Yong, Choi, Young Hwa, Chotiprasitsakul, Darunee, Chung, Jin Won, Danion, François, Denis, Blandine, Diaz Santos, Emilio, Dictar, Miguel O, Diltoer, Marc, Dupont, Herve, Feng, Sizhou, Ferre Colomer, Maria Angeles, Ferrer, Ricard, Forel, Jean-Marie Fernand Roger, Fortún-Abete, Jesús, Garcia-Diaz, Julia, Girardis, Massimo, He, Fang, Hites, Maya, Ho, Mao-Wang, Honore, Patrick, Horcajada Gallego, Juan Pablo, Huang, Haihui, Huang, Po-Yen, Huang, Yong, Hussein, Osamah, Intalapaporn, Poj, Jaruratanasirikul, Sutep, Jauregui-Peredo, Luis, Johnson, Misty, Jung, Dong Sik, Jutivorakool, Kamonwan, Kern, Winfried V, Kett, Daniel H, Khawcharoenporn, Thana, Kim, Young Keun, Koehler, Philipp, Kotanidou, Anastasia, Lachiewicz, Anne, Lin, Qinhan, Lopez Cortes, Luis Eduardo, Luo, Hong, Luzzati, Roberto, Maor, Yasmin, McCarty, Todd, Merelli, Maria, Merino Amador, Paloma, Midturi, John, Migliorino, Guglielmo Marco, Mira, Jean-Paul, Mootsikapun, Piroon, Morrissey, Orla, Munoz Garcia de Paredes, Patricia, Mussini, Cristina, Mylonakis, Eleftherios, Nseir, Saadalla, Nseir, William, Odabasi, Zekaver, Papastamopoulos, Vasileios, Paterson, David, Patterson, Thomas F, Peck, Kyong Ran, Peng, Zhiyong, Permpalung, Nitipong, Plantefeve, Gaetan J, Poromanski, Ivan G, Powell, Debra, Psichogiou, Mina, Puah, Ser Hon, Pullman, John, Rahav, Galia, Martinez, Antonio Ramos, Ramos Ramos, Juan Carlos, Raz-Pasteur, Ayelet, Restrepo Castro, Carlos A, Riera, Fernando, Roblot, France, Rodriguez Alvarez, Regino Jose, Rogers, Benjamin, Roilides, Emmanuel, Sanchez Vallejo, Gregorio, Sganga, Gabriele, Sipsas, Nikolaos, Slavin, Monica, Soriano, Alex, Spec, Andrej, Strahilevitz, Jacob, Tancheva, Dora M, Tao, Zhen, Teschner, Daniel, Thompson, George R, Van Wijngaerden, Eric, Vazquez, Jose, Vergidis, Paschalis, Viale, Pierluigi, Wang, Fu-Der, Wang, Shifu, Weber, Gabriel, Weng, Jianyu, Xu, Jinfu, Yao, Li, Yavuz, Serap, Yilmaz, Mesut, Young, Jo-Anne, Zarate, Abel H, Zeng, Jun, Zhang, Yong, Thompson, George R, III, Cornely, Oliver A, Kullberg, Bart Jan, Kollef, Marin, Honore, Patrick M, Bassetti, Matteo, Poromanski, Ivan, Dignani, Cecilia, Das, Anita F, Sandison, Taylor, and Pappas, Peter G

Published
2023
Full Text
View/download PDF

8. Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece

Author

Roussos, Sotirios, primary, Bagos, Christos, additional, Angelopoulos, Theodoros, additional, Chaikalis, Savvas, additional, Cholongitas, Evangelos, additional, Savvanis, Spyridon, additional, Papadopoulos, Nikolaos, additional, Kapatais, Andreas, additional, Chounta, Athina, additional, Ioannidou, Panagiota, additional, Deutsch, Melani, additional, Manolakopoulos, Spilios, additional, Sevastianos, Vasileios, additional, Papageorgiou, Maria‐Vasiliki, additional, Vlachogiannakos, Ioannis, additional, Mela, Maria, additional, Elefsiniotis, Ioannis, additional, Vrakas, Spyridon, additional, Karagiannakis, Dimitrios, additional, Pliarchopoulou, Fani, additional, Psichogiou, Mina, additional, Paraskevis, Dimitrios, additional, Vickerman, Peter, additional, Malliori, Meni, additional, Kalamitsis, Georgios, additional, Papatheodoridis, Georgios, additional, Hatzakis, Angelos, additional, and Sypsa, Vana, additional

Published
2024
Full Text
View/download PDF

9. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study

Author

Staessen, Jan A, Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Lazo, Mercedes Salgueira, Psichogiou, Mina, Rajzer, Marek W, Fulawka, Lukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald, Czerwienska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, Beige, Joachim, Ermisch, Jörg, Kellner, Nils, Peruth-Stutzmann, Lydia, Schroth, Stefanie, Schmidt, Jonathan, Schmidt, Ulrike, Breuer, Daniel, Abeud, Fariza, Fournier, Marie-Celine, Louadah, Badr, Molas, Rocio, Rojas, Fraile Loreto, García, Fabiola Alonso, Sánchez, Isabel Garcia, Hrom, Ioana Cezara, Więczek., Andrzej, Schwab, Matthias, K Asayama, Kei, Hansen, Tine W, Maestre, Gladys E, Basoulis, Dimitrios, Karamanakos., Georgios, Lis, Pawel, Olszanecka, Agnieszka, Bellmann-Weiler, Rosa, Lanser, Lucas, Edin, Alicia, Forsell, Matthias NE, Stegmayr, Bernd, Jensen, Björn-Erik Ole, Orth, Hans-Martin, Borstel, Sylke, Mikolajewska, Agata, Hecking, Manfred, Schmölz, Lukas, Hoffmann, Michał, Narkiewicz, Krzysztof, Matera-Witkiewicz, Agnieszka, Zachciał, Justyna, Litwin, Monika, Marciniak, Patrycja, Salgueira Lazo, Mercedes, Fuławka, Łukasz, Rupprecht, Harald D, and Czerwieńska, Beata

Published
2022
Full Text
View/download PDF

10. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study

Author

Trickey, Adam, Zhang, Lei, Gill, M John, Bonnet, Fabrice, Burkholder, Greer, Castagna, Antonella, Cavassini, Matthias, Cichon, Piotr, Crane, Heidi, Domingo, Pere, Grabar, Sophie, Guest, Jodie, Obel, Niels, Psichogiou, Mina, Rava, Marta, Reiss, Peter, Rentsch, Christopher T, Riera, Melchor, Schuettfort, Gundolf, Silverberg, Michael J, Smith, Colette, Stecher, Melanie, Sterling, Timothy R, Ingle, Suzanne M, Sabin, Caroline A, and Sterne, Jonathan A C

Published
2022
Full Text
View/download PDF

13. HCV‐HIV co‐infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.

Author

Basoulis, Dimitris, Mastrogianni, Elpida, Eliadi, Irene, Papadopoulou, Martha, and Psichogiou, Mina

Subjects
RISK assessment, SCIENTIFIC observation, SOCIOECONOMIC factors, HIV infections, DESCRIPTIVE statistics, ANTIVIRAL agents, LONGITUDINAL method, ODDS ratio, NARCOTICS, HEPATITIS C, CONFIDENCE intervals, INTRAVENOUS drug abusers, PSYCHOSOCIAL factors, MIXED infections
Abstract

Objectives: HIV/hepatitis C virus (HCV) co‐infection among people who inject drugs (PWID) remains a global health problem. The goal of our study was to evaluate, in a real‐world setting, success rates of sustained virological response (SVR) using direct‐acting antivirals (DAAs) to treat a population of PWID living with HCV/HIV. Methods: This was a prospective single‐center observational study. We collected demographic, socioeconomic, and clinical data pertaining to HIV and HCV infection in PWID with several barriers to care. We identified risk factors for SVR failure. Results: Among 130 individuals retained to HIV care, we planned HCV treatment in 119/130 (91.5%); 106/119 (89.1%) started treatment with DAAs and 100/106 (94.3%) completed treatment. People not starting treatment were more often in active opioid drug use (odds ratio [OR] 0.25; 95% confidence interval [CI] 0.07–0.97, p = 0.045) and benzodiazepine abuse (OR 0.25; 95% CI 0.07–0.95, p = 0.042). Only 86/100 (86%) were tested for SVR at 12 weeks (SVR12) and 72/86 (83.7%) achieved SVR. PWID in opioid substitution programmes tended to return for SVR12 testing more often (54.7% vs. 30%, p = 0.081). Individuals in active opioid drug use (OR 0.226; 95% CI 0.064–0.793, p = 0.02) or with poor adherence (OR 0.187; 95% CI 0.043–0.814, p = 0.025) were less likely to achieve SVR. At the end of our study period, 113/119 (95%) treatment‐eligible patients remained alive. HCV infection was cured in 68/113 (61.1%) people. Conclusions: Our findings underscore the importance of prioritizing combatting substance use to achieve HCV elimination goals. A systematic approach with effort to overcome barriers to receiving and completing treatment and encourage to enrol in opioid substitution programmes if not possible to completely abstain from use, can help increase chances of HCV cure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH)

Author

Nitsotolis, Thomas, primary, Kyriakoulis, Konstantinos G., additional, Kollias, Anastasios, additional, Papalexandrou, Alexia, additional, Kalampoka, Helen, additional, Mastrogianni, Elpida, additional, Basoulis, Dimitrios, additional, and Psichogiou, Mina, additional

Published
2024
Full Text
View/download PDF

15. A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP).

Author

Nikolopoulos, Georgios, Pavlitina, Eirini, Muth, Stephen, Schneider, John, Psichogiou, Mina, Williams, Leslie, Paraskevis, Dimitrios, Sypsa, Vana, Magiorkinis, Gkikas, Smyrnov, Pavlo, Korobchuk, Anya, Skaathun, Britt, Malliori, Melpomeni, Kafetzopoulos, Evangelos, Hatzakis, Angelos, Friedman, Samuel, and Vasylyeva, Tetyana

Subjects
Adult, Female, Greece, HIV Infections, Humans, Male, Public Health, Social Support
Abstract

Early treatment, soon after infection, reduces HIV transmissions and benefits patients. The Transmission Reduction Intervention Project (TRIP) evaluated a network intervention to detect individuals recently infected (in the past 6 months). TRIP was conducted in Greece (2013-2015) and focused on drug injector networks. Based on HIV status, testing history, and the results of an assay to detect recent infections, TRIP classified drug injector Seeds into groups: Recent Seeds (RS), and Control Seeds with Long-term HIV infection (LCS). The network members of RS and LCS were traced for two steps. The analysis included 23 RS, 171 network members of the RS, 19 LCS, and 65 network members of the LCS. The per-seed number of recents detected in the network of RS was 5 times the number in the network of LCS (Ratio RS vs. LCS: 5.23; 95% Confidence Interval (CI): 1.54-27.61). The proportion of recents among HIV positives in the network of RS (27%) was approximately 3 times (Ratio RS vs. LCS: 3.30; 95% CI: 1.04-10.43) that in the network of LCS (8%). Strategic network tracing that starts with recently infected persons could support public health efforts to find and treat people early in their HIV infection.

Published
2016

16. Molecular Epidemiology of HIV Among People Who Inject Drugs after the Hiv-Outbreak in Athens, Greece: Evidence for a ‘Slow Burn’ Outbreak

Author

Kostaki, Evangelia Georgia, primary, Roussos, Sotirios, additional, Kefala, Anastasia Maria, additional, Limnaios, Stefanos, additional, Psichogiou, Mina, additional, Papachristou, Eleni, additional, Nikolopoulos, Georgios K., additional, Flountzi, Eleni, additional, Friedman, Samuel R., additional, Lagiou, Pagona, additional, Hatzakis, Angelos, additional, Sypsa, Vana, additional, Magiorkinis, Gkikas, additional, Beloukas, Apostolos, additional, and Paraskevis, Dimitrios, additional

Published
2024
Full Text
View/download PDF

17. The impact of frailty and illness perceptions on quality of life among people living with HIV in Greece: A network analysis

Author

Kapetanakis, Anargyros, primary, Karakatsoulis, Georgios, additional, Kyrou, Dimitrios, additional, Ntourou, Iliana, additional, Vrontaras, Nikolaos, additional, Tsachouridou, Olga, additional, Meliou, Maria, additional, Basoulis, Dimitrios, additional, Protopapas, Konstantinos, additional, Petrakis, Vasilis, additional, Leonidou, Leonidia, additional, Katsarolis, Ioannis, additional, Metallidis, Simeon, additional, Chini, Maria, additional, Psichogiou, Mina, additional, Antoniadou, Anastasia, additional, Panagopoulos, Periklis, additional, Gogos, Charalambos, additional, and Karamanidou, Christina, additional

Published
2023
Full Text
View/download PDF

19. Socially-integrated transdisciplinary HIV prevention.

Author

Friedman, Samuel, Downing, Martin, Smyrnov, Pavlo, Nikolopoulos, Georgios, Schneider, John, Livak, Britt, Magiorkinis, Gkikas, Slobodianyk, Liudmyla, Paraskevis, Dimitrios, Psichogiou, Mina, Sypsa, Vana, Malliori, Melpomeni, Hatzakis, Angelos, and Vasylyeva, Tetyana

Subjects
Condoms, HIV Infections, Health Education, Health Knowledge, Attitudes, Practice, Healthcare Disparities, Humans, Interdisciplinary Communication, Phylogeny, Program Evaluation, Public Health, Quality Improvement, Quality of Health Care, Risk Reduction Behavior, Risk-Taking, Time Factors, Viral Load
Abstract

Current ideas about HIV prevention include a mixture of primarily biomedical interventions, socio-mechanical interventions such as sterile syringe and condom distribution, and behavioral interventions. This article presents a framework for socially-integrated transdisciplinary HIV prevention that may improve current prevention efforts. It first describes one socially-integrated transdisciplinary intervention project, the Transmission Reduction Intervention Project. We focus on how social aspects of the intervention integrate its component parts across disciplines and processes at different levels of analysis. We then present socially-integrated perspectives about how to improve combination antiretroviral treatment (cART) processes at the population level in order to solve the problems of the treatment cascade and make treatment as prevention more effective. Finally, we discuss some remaining problems and issues in such a social transdisciplinary intervention in the hope that other researchers and public health agents will develop additional socially-integrated interventions for HIV and other diseases.

Published
2014

20. Characteristics of the Genetic Spread of Carbapenem-Resistant Acinetobacter baumannii in a Tertiary Greek Hospital.

Author

Papadopoulou, Martha, Deliolanis, Ioannis, Polemis, Michalis, Vatopoulos, Alkiviadis, Psichogiou, Mina, and Giakkoupi, Panagiota

Subjects
CARBAPENEM-resistant bacteria, ACINETOBACTER baumannii, PULSED-field gel electrophoresis, NOSOCOMIAL infections, MOLECULAR epidemiology, HOSPITALS, INTENSIVE care units
Abstract

Acinetobacter baumannii (Ab) has increasingly been identified as a cause of hospital-acquired infections and epidemics. The rise of carbapenem-resistant Acinetobacter baumannii (CRAB) poses significant challenges in treatment. Nosocomial outbreaks linked to CRAΒ A. baumannii strains have been reported worldwide, including in Greece. This study aimed to analyze the molecular epidemiology trends of multidrug-resistant A. baumannii isolates in a tertiary hospital in Athens, Greece. A total of 43 clinical isolates of extensively drug-resistant (XDRAB), pan-drug-resistant (PDRAB), and CRAB were collected from patients suffering from blood infection, hospitalized between 2016 and 2020 at the internal medicine clinics and the ICU. A.baumannii isolates underwent testing for Ambler class B and D carbapenemases and the detection of ISAba1, and were typed, initially, using pulsed-field gel electrophoresis, and, subsequently, using sequence-based typing and multiplex PCR to determine European Clone lineages. The blaOXA-23 gene accompanied by ISAba1 was prevalent in nearly all A. baumannii isolates, except for one carrying blaOXA-58. The intrinsic blaOXA-51-like gene was found in all isolates. No Ambler class B carbapenemases (VIM, NDM) were detected. Isolates were grouped into four PF-clusters and no one-cluster spread was documented, consistent with the absence of outbreak. The study indicated that XDR/PDR-CRAB isolates predominantly produce OXA-23 carbapenemase and belong to European Clone II. Further research is needed to understand the distribution of resistant bacteria and develop effective prevention and control strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)–Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project) : Phylogenetics Identify HIV-1–Infected Individuals With Social Links

Author

Kostaki, Evangelia-Georgia, Nikolopoulos, Georgios K., Pavlitina, Eirini, Williams, Leslie, Magiorkinis, Gkikas, Schneider, John, Skaathun, Britt, Morgan, Ethan, Psichogiou, Mina, Daikos, Georgios L., Sypsa, Vana, Smyrnov, Pavlo, Korobchuk, Ania, Malliori, Meni, Hatzakis, Angelos, Friedman, Samuel R., and Paraskevis, Dimitrios

Published
2018

31. Validation of Sequential ROX-Index Score Beyond 12 Hours in Predicting Treatment Failure and Mortality in COVID-19 Patients Receiving Oxygen via High-Flow Nasal Cannula

Author

Basoulis, Dimitris, primary, Avramopoulos, Pantelis, additional, Aggelara, Maria, additional, Karamanakos, Georgios, additional, Voutsinas, Pantazis-Michail, additional, Karapanou, Amalia, additional, Psichogiou, Mina, additional, Samarkos, Michalis, additional, Ntziora, Foteini, additional, and Sipsas, Nikolaos V., additional

Published
2023
Full Text
View/download PDF

33. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Author

Thompson, George R, primary, Soriano, Alex, additional, Cornely, Oliver A, additional, Kullberg, Bart Jan, additional, Kollef, Marin, additional, Vazquez, Jose, additional, Honore, Patrick M, additional, Bassetti, Matteo, additional, Pullman, John, additional, Chayakulkeeree, Methee, additional, Poromanski, Ivan, additional, Dignani, Cecilia, additional, Das, Anita F, additional, Sandison, Taylor, additional, Pappas, Peter G, additional, Akova, Murat, additional, AlAgha, Rawan, additional, Alangaden, George, additional, Albrecht, Svenja J, additional, Alexander, Barbara, additional, Al-Obaidi, Mohanad, additional, Ambasch, German, additional, Armestar Rodriguez, Fernando, additional, Azap, Alpay, additional, Baffoe-Bonnie, Anthony, additional, Belkhir, Leila, additional, Ben-Ami, Ronen, additional, Boutoille, David, additional, Cascio, Antonio, additional, Chai, Louis YA, additional, Chaiwarith, Romanee, additional, Chen, Sharon, additional, Chen, Yee-Chun, additional, Chen, Yen-Hsu, additional, Choi, Jun Yong, additional, Choi, Young Hwa, additional, Chotiprasitsakul, Darunee, additional, Chung, Jin Won, additional, Danion, François, additional, Denis, Blandine, additional, Diaz Santos, Emilio, additional, Dictar, Miguel O, additional, Diltoer, Marc, additional, Dupont, Herve, additional, Feng, Sizhou, additional, Ferre Colomer, Maria Angeles, additional, Ferrer, Ricard, additional, Forel, Jean-Marie Fernand Roger, additional, Fortún-Abete, Jesús, additional, Garcia-Diaz, Julia, additional, Girardis, Massimo, additional, He, Fang, additional, Hites, Maya, additional, Ho, Mao-Wang, additional, Honore, Patrick, additional, Horcajada Gallego, Juan Pablo, additional, Huang, Haihui, additional, Huang, Po-Yen, additional, Huang, Yong, additional, Hussein, Osamah, additional, Intalapaporn, Poj, additional, Jaruratanasirikul, Sutep, additional, Jauregui-Peredo, Luis, additional, Johnson, Misty, additional, Jung, Dong Sik, additional, Jutivorakool, Kamonwan, additional, Kern, Winfried V, additional, Kett, Daniel H, additional, Khawcharoenporn, Thana, additional, Kim, Young Keun, additional, Koehler, Philipp, additional, Kotanidou, Anastasia, additional, Lachiewicz, Anne, additional, Lin, Qinhan, additional, Lopez Cortes, Luis Eduardo, additional, Luo, Hong, additional, Luzzati, Roberto, additional, Maor, Yasmin, additional, McCarty, Todd, additional, Merelli, Maria, additional, Merino Amador, Paloma, additional, Midturi, John, additional, Migliorino, Guglielmo Marco, additional, Mira, Jean-Paul, additional, Mootsikapun, Piroon, additional, Morrissey, Orla, additional, Munoz Garcia de Paredes, Patricia, additional, Mussini, Cristina, additional, Mylonakis, Eleftherios, additional, Nseir, Saadalla, additional, Nseir, William, additional, Odabasi, Zekaver, additional, Papastamopoulos, Vasileios, additional, Paterson, David, additional, Patterson, Thomas F, additional, Peck, Kyong Ran, additional, Peng, Zhiyong, additional, Permpalung, Nitipong, additional, Plantefeve, Gaetan J, additional, Poromanski, Ivan G, additional, Powell, Debra, additional, Psichogiou, Mina, additional, Puah, Ser Hon, additional, Rahav, Galia, additional, Martinez, Antonio Ramos, additional, Ramos Ramos, Juan Carlos, additional, Raz-Pasteur, Ayelet, additional, Restrepo Castro, Carlos A, additional, Riera, Fernando, additional, Roblot, France, additional, Rodriguez Alvarez, Regino Jose, additional, Rogers, Benjamin, additional, Roilides, Emmanuel, additional, Sanchez Vallejo, Gregorio, additional, Sganga, Gabriele, additional, Sipsas, Nikolaos, additional, Slavin, Monica, additional, Spec, Andrej, additional, Strahilevitz, Jacob, additional, Tancheva, Dora M, additional, Tao, Zhen, additional, Teschner, Daniel, additional, Thompson, George R, additional, Van Wijngaerden, Eric, additional, Vergidis, Paschalis, additional, Viale, Pierluigi, additional, Wang, Fu-Der, additional, Wang, Shifu, additional, Weber, Gabriel, additional, Weng, Jianyu, additional, Xu, Jinfu, additional, Yao, Li, additional, Yavuz, Serap, additional, Yilmaz, Mesut, additional, Young, Jo-Anne, additional, Zarate, Abel H, additional, Zeng, Jun, additional, and Zhang, Yong, additional

Published
2023
Full Text
View/download PDF

34. Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock‐inferred dates: Evidence that older age, heterosexual risk group and more recent diagnosis are prognostic factors

Author

Kostaki, Evangelia Georgia, primary, Limnaios, Stefanos, additional, Adamis, Georgios, additional, Xylomenos, Georgios, additional, Chini, Maria, additional, Mangafas, Nikos, additional, Lazanas, Marios, additional, Patrinos, Stavros, additional, Metallidis, Simeon, additional, Tsachouridou, Olga, additional, Papastamopoulos, Vasileios, additional, Chatzidimitriou, Dimitrios, additional, Antoniadou, Anastasia, additional, Papadopoulos, Antonios, additional, Protopapas, Konstantinos, additional, Tsiara, Chrysa, additional, Psichogiou, Mina, additional, Basoulis, Dimitrios, additional, Pilalas, Dimitrios, additional, Paraskeva, Dimitra, additional, Chrysos, Georgios, additional, Paparizos, Vasileios, additional, Kourkounti, Sofia, additional, Sambatakou, Helen, additional, Bolanos, Vasileios, additional, Sipsas, Nikolaos V., additional, Lada, Malvina, additional, Barbounakis, Emmanouil, additional, Kantzilaki, Evrikleia, additional, Panagopoulos, Periklis, additional, Petrakis, Vasilis, additional, Drimis, Stelios, additional, Katsarolis, Ioannis, additional, Lagiou, Pagona, additional, Hatzakis, Angelos, additional, Magiorkinis, Gkikas, additional, Skoura, Lemonia, additional, and Paraskevis, Dimitrios, additional

Published
2022
Full Text
View/download PDF

35. High levels of all-cause mortality among people who inject drugs in Greece in 2018–2022

Author

Rousssos, Sotirios, primary, Angelopoulos, Theodoros, additional, Cholongitas, Evangelos, additional, Savvanis, Spyridon, additional, Papadopoulos, Nikolaos, additional, Kapatais, Andreas, additional, Hounta, Athina, additional, Ioannidou, Panagiota, additional, Deutsch, Melani, additional, Manolakopoulos, Spilios, additional, Sevastianos, Vasileios, additional, Papageorgiou, Maria-Vasiliki, additional, Vlachogiannakos, Ioannis, additional, Mela, Maria, additional, Elefsiniotis, Ioannis, additional, Vrakas, Spyridon, additional, Karagiannakis, Dimitrios, additional, Pliarchopoulou, Fani, additional, Chaikalis, Savvas, additional, Tsirogianni, Effrosyni, additional, Psichogiou, Mina, additional, Kalamitsis, Georgios, additional, Leobilla, Foteini, additional, Paraskevis, Dimitrios, additional, Malliori, Meni, additional, Goulis, Ioannis, additional, Papatheodoridis, Georgios, additional, Hatzakis, Angelos, additional, and Sypsa, Vana, additional

Published
2022
Full Text
View/download PDF

36. Predictive score for patients with carbapenemase-producing enterobacterales colonization upon admission in a tertiary care hospital in an endemic area

Author

Papafotiou, Chrysanthe, primary, Roussos, Sotirios, additional, Sypsa, Vana, additional, Bampali, Sofia, additional, Spyridopoulou, Kalliopi, additional, Karapanou, Amalia, additional, Moussouli, Anastasia, additional, Samarkos, Michael, additional, Daikos, George L, additional, and Psichogiou, Mina, additional

Published
2022
Full Text
View/download PDF

37. A Comparative Study on the Presence and Reversibility of Subclinical Arterial Damage in HCV-Infected Individuals and Matched Controls.

Author

Androutsakos, Theodoros, Mouziouras, Dimitrios, Katelani, Stamatia, Psichogiou, Mina, Sfikakis, Petros P., Protogerou, Athanase D., and Argyris, Antonios A.

Subjects
ANTIRHEUMATIC agents, PULSE wave analysis, HIV-positive persons, ANTIVIRAL agents, RHEUMATOID arthritis
Abstract

Background: The arterial pathology and mechanisms of increased cardiovascular disease (CVD) risk in HCV-infected individuals are not yet clear. The aim of this study was to identify types of arterial pathology in treatment-naive chronic HCV patients and to test their reversibility after successful treatment. Methods: Consecutive, never-treated, HCV-infected patients were compared with age and CVD-related risk factors, matched controls, healthy individuals (HI), patients with rheumatoid arthritis (RA) and people living with HIV (PLWH), in terms of arterial stiffening by pulse wave velocity, arterial atheromatosis/hypertrophy by carotid plaques/intima-media thickness and impaired pressure wave reflections by augmentation index. After three months of sustained virological response (SVR) administered using direct-acting antivirals, vascular examination was repeated in HCV-infected patients to test drug and viral-elimination effect in subclinical CVD. Results: Thirty HCV patients were examined at baseline; fourteen of them were re-examined post-SVR. Compared with HI, HCV patients had significantly more plaques, which is similar to that of RA patients and the PLWH group. No other differences were found in all other vascular biomarkers, and regression among HCV patients also revealed no differences 3 months post-SVR. Conclusions: Accelerated atheromatosis, rather than arterial stiffening, arterial remodeling and peripheral impaired hemodynamics is the underlying pathology leading to increased CVD risk in HCV patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug

Author

Pantazis, Nikos, primary, Papastamopoulos, Vasilios, additional, Antoniadou, Anastasia, additional, Adamis, Georgios, additional, Paparizos, Vasilios, additional, Metallidis, Simeon, additional, Sambatakou, Helen, additional, Psichogiou, Mina, additional, Chini, Maria, additional, Chrysos, Georgios, additional, Panagopoulos, Periklis, additional, Sipsas, Nikolaos V., additional, Barbunakis, Emmanouil, additional, Gogos, Charalambos, additional, and Touloumi, Giota, additional

Published
2022
Full Text
View/download PDF

39. Mapping frailty in people living with HIV : A nationwide study in Greece

Author

Tsakona, Dimitra, primary, Kapetanakis, Anargyros, additional, Kyrou, Dimitrios, additional, Vrontaras, Nikolaos, additional, Xochelli, Aliki, additional, Metallidis, Simeon, additional, Tsachouridou, Olga, additional, Chini, Maria, additional, Meliou, Maria, additional, Psichogiou, Mina, additional, Basoulis, Dimitrios, additional, Antoniadou, Anastasia, additional, Protopapas, Konstantinos, additional, Panagopoulos, Periklis, additional, Petrakis, Vasilis, additional, Gogos, Charalambos, additional, Leonidou, Leonidia, additional, and Karamanidou, Christina, additional

Published
2022
Full Text
View/download PDF

40. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia

Author

Gkoufa, Aikaterini, primary, Sou, Tomás, additional, Karaiskos, Ilias, additional, Routsi, Christina, additional, Lin, Yu-Wei, additional, Psichogiou, Mina, additional, Zakynthinos, Spyros, additional, Giamarellou, Helen, additional, Li, Jian, additional, and Friberg, Lena E., additional

Published
2022
Full Text
View/download PDF

42. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia

Author

Gkoufa, Aikaterini, Sou, Tomas, Karaiskos, Ilias, Routsi, Christina, Lin, Yu-Wei, Psichogiou, Mina, Zakynthinos, Spyros, Giamarellou, Helen, Li, Jian, Friberg, Lena, Gkoufa, Aikaterini, Sou, Tomas, Karaiskos, Ilias, Routsi, Christina, Lin, Yu-Wei, Psichogiou, Mina, Zakynthinos, Spyros, Giamarellou, Helen, Li, Jian, and Friberg, Lena

Abstract

There has been accumulating interest in nebulised colistin methanesulfonate (CMS) for the treatment of ventilator-associated pneumonia (VAP). In this study, pulmonary and systemic pharmacokinetics following nebulisation of CMS at a dose of 3 MIU and 5 MIU, using a vibrating mesh nebuliser, for VAP caused by extensively drug-resistant Gram-negative pathogens was assessed. Blood samples and minibronchoalveolar lavage (mini-BAL) was performed post-dose at 1, 4 and 8 h. Concentrations of CMS and formed colistin in mini-BAL and plasma were determined by liquid chromatography-tandem mass spectrometry, and pharmacokinetic analysis was conducted using a population approach. The study population included three groups ( n = 10 per group): (A) intravenous CMS and concomitantly nebulised CMS at a dose of 3 MIU (30 min duration); (B) nebulised CMS at a dose of 3 MIU (30 min duration) as monotherapy; and (C) nebulised CMS 5 MIU (45 min duration) as monotherapy. Mean plasma formed colistin concentrations were < 1 mg/L following CMS nebulisation as monotherapy (groups B and C). Predicted trough concentrations of formed colistin in the epithelial lining fluid (ELF) following 24-h dosing of 3 MIU and 5 MIU nebulised CMS were 120.4 mg/L and 200.7 mg/L, respectively. The model predicted that concomitant intravenous CMS (group A) had minimal impact on the formed colistin concentration in ELF. This study demonstrated high ELF formed colistin concentrations following nebulised CMS (constantly above colistin MICs), while plasma concentrations were lower than those associated with nephrotoxicity. Our results provide important information for optimisation of nebulised colistin therapy. (c) 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Published
2022
Full Text
View/download PDF

43. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection : a prospective multicentre cohort study

Author

Staessen, Jan A., Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Salgueira Lazo, Mercedes, Psichogiou, Mina, Rajzer, Marek W., Fuławka, Łukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald D., Czerwieńska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, Beige, Joachim, Staessen, Jan A., Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Salgueira Lazo, Mercedes, Psichogiou, Mina, Rajzer, Marek W., Fuławka, Łukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald D., Czerwieńska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, and Beige, Joachim

Abstract

Background: The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker. Methods: CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product of each country. Findings: From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021, 784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1–3 in 445 (44%) participants, 4–5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI 2·05–2·92) unadjusted and 1·67 (1·34–2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO score; and for disease progression, the OR was 1·79 (1·60–2·01) when unadjusted and 1·63 (1·41–1·91) when adjusted (p<0·0001 for all). The predictive accuracy of the optimised COV50

Published
2022
Full Text
View/download PDF

44. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America:a cohort study

Author

Trickey, Adam, Zhang, Lei, Gill, M. John, Bonnet, Fabrice, Burkholder, Greer, Castagna, Antonella, Cavassini, Matthias, Cichon, Piotr, Crane, Heidi, Domingo, Pere, Grabar, Sophie, Guest, Jodie, Obel, Niels, Psichogiou, Mina, Rava, Marta, Reiss, Peter, Rentsch, Christopher T., Riera, Melchor, Schuettfort, Gundolf, Silverberg, Michael J., Smith, Colette, Stecher, Melanie, Sterling, Timothy R., Ingle, Suzanne M., Sabin, Caroline A., Sterne, Jonathan A.C., Trickey, Adam, Zhang, Lei, Gill, M. John, Bonnet, Fabrice, Burkholder, Greer, Castagna, Antonella, Cavassini, Matthias, Cichon, Piotr, Crane, Heidi, Domingo, Pere, Grabar, Sophie, Guest, Jodie, Obel, Niels, Psichogiou, Mina, Rava, Marta, Reiss, Peter, Rentsch, Christopher T., Riera, Melchor, Schuettfort, Gundolf, Silverberg, Michael J., Smith, Colette, Stecher, Melanie, Sterling, Timothy R., Ingle, Suzanne M., Sabin, Caroline A., and Sterne, Jonathan A.C.

Abstract

Background: Over the past decade, antiretroviral therapy (ART) regimens that include integrase strand inhibitors (INSTIs) have become the most commonly used for people with HIV starting ART. Although trials and observational studies have compared virological failure on INSTI-based with other regimens, few data are available on mortality in people with HIV treated with INSTIs in routine care. Therefore, we compared all-cause mortality between different INSTI-based and non-INSTI-based regimens in adults with HIV starting ART from 2013 to 2018. Methods: This cohort study used data on people with HIV in Europe and North America from the Antiretroviral Therapy Cohort Collaboration (ART-CC) and UK Collaborative HIV Cohort (UK CHIC). We studied the most common third antiretroviral drugs (additional to nucleoside reverse transcriptase inhibitor) used from 2013 to 2018: rilpivirine, darunavir, raltegravir, elvitegravir, dolutegravir, efavirenz, and others. Adjusted hazard ratios (aHRs; adjusted for clinical and demographic characteristics, comorbid conditions, and other drugs in the regimen) for mortality were estimated using Cox models stratified by ART start year and cohort, with multiple imputation of missing data. Findings: 62 500 ART-naive people with HIV starting ART (12 422 [19·9%] women; median age 38 [IQR 30–48]) were included in the study. 1243 (2·0%) died during 188 952 person-years of follow-up (median 3·0 years [IQR 1·6–4·4]). There was little evidence that mortality rates differed between regimens with dolutegravir, elvitegravir, rilpivirine, darunavir, or efavirenz as the third drug. However, mortality was higher for raltegravir compared with dolutegravir (aHR 1·49, 95% CI 1·15–1·94), elvitegravir (1·86, 1·43–2·42), rilpivirine (1·99, 1·49–2·66), darunavir (1·62, 1·33–1·98), and efavirenz (2·12, 1·60–2·81) regimens. Results were similar for analyses making different assumptions about missing data and consistent across the time periods 2013–15 and 2016–18. R

Published
2022

45. Mapping frailty in people living with HIV: A nationwide study in Greece.

Author

Tsakona, Dimitra, Kapetanakis, Anargyros, Kyrou, Dimitrios, Vrontaras, Nikolaos, Xochelli, Aliki, Metallidis, Simeon, Tsachouridou, Olga, Chini, Maria, Meliou, Maria, Psichogiou, Mina, Basoulis, Dimitrios, Antoniadou, Anastasia, Protopapas, Konstantinos, Panagopoulos, Periklis, Petrakis, Vasilis, Gogos, Charalambos, Leonidou, Leonidia, and Karamanidou, Christina

Subjects
BIOMARKERS, RESEARCH, CENTRAL nervous system diseases, FRAIL elderly, CROSS-sectional method, VIRAL load, POLYPHARMACY, RISK assessment, SURVEYS, QUESTIONNAIRES, DISEASE prevalence, DESCRIPTIVE statistics, CD4 lymphocyte count, RESEARCH funding, SOCIODEMOGRAPHIC factors, NEEDS assessment, PSYCHOLOGY of HIV-positive persons, MEDICAL needs assessment, PHENOTYPES, AIDS, MENTAL illness
Abstract

Objectives: Frailty is known to affect people living with HIV prematurely, compared to the ageing seronegative population. In this cross‐sectional study, we aimed to assess frailty prevalence in people living with HIV in Greece and find associations of frailty criteria with clinical data. Methods: Demographic and clinical data were collected from 477 participants in six HIV clinics. Fried's frailty phenotype was used to assess frailty prevalence, and participants were classified as frail, pre‐frail or robust. Associations of several factors with overall frailty phenotype, as well as with frailty criteria, were explored. Results: The median age was 43 years old (IQR = 51.5) and 444/477 (93%) were men. Most of the participants (429/477, 93.5%) had an undetectable HIV viral load, and a CD4 cell count over 500 cells/μl (366/477, 76.7%). Frailty assessment classified 285/477 (62.1%) as robust, 155/477 (33.8%) as pre‐frail and 19/477 (4.1%) as frail. Weakness in grip strength was the most prevalent criterion (128/477, 26.8%), followed by exhaustion (46/477, 9.6%). Lower CD4 cell count, history of AIDS diagnosis, CNS disorders, psychiatric diagnoses, and polypharmacy were strongly associated with frailty. Conclusions: Although the prevalence of frailty in people living with HIV in Greece is uncommon, when combined with pre‐frailty over a third of people are affected, which requires attention in clinical practice. The physical and psychological aspects of frailty highlight the need for a holistic approach to prevent or counteract it. The diverse associations of frailty criteria with HIV‐related and non‐HIV‐related factors suggest a possible variation in people's different healthcare needs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. An exploration of the quality of life of people living with HIV in Greece: Challenges and opportunities

Author

Vrontaras, Nikolaos, primary, Myrvali, Katerina, additional, Kyrou, Dimitrios, additional, Metallidis, Simeon, additional, Tsachouridou, Olga, additional, Chini, Maria, additional, Meliou, Maria, additional, Psichogiou, Mina, additional, Basoulis, Dimitrios, additional, Antoniadou, Anastasia, additional, Protopapas, Konstantinos, additional, Panagopoulos, Periklis, additional, Petrakis, Vasilis, additional, Gogos, Charalambos, additional, Leonidou, Lydia, additional, and Karamanidou, Christina, additional

Published
2022
Full Text
View/download PDF

47. A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients

Author

Georgakopoulou, Vasiliki E., primary, Vlachogiannis, Nikolaos I., additional, Basoulis, Dimitrios, additional, Eliadi, Irene, additional, Georgiopoulos, Georgios, additional, Karamanakos, Georgios, additional, Makrodimitri, Sotiria, additional, Samara, Stamatia, additional, Triantafyllou, Maria, additional, Voutsinas, Pantazis M., additional, Ntziora, Fotinie, additional, Psichogiou, Mina, additional, Samarkos, Michael, additional, Sfikakis, Petros P., additional, and Sipsas, Nikolaos V., additional

Published
2022
Full Text
View/download PDF

48. Subclinical Left Ventricular Systolic Dysfunction in HIV Patients: Prevalence and Associations with Carotid Atherosclerosis and Increased Adiposity

Author

Athanasiadi, Eleni, primary, Bonou, Maria, additional, Basoulis, Dimitrios, additional, Kapelios, Chris J., additional, Masoura, Constantina, additional, Skouloudi, Marina, additional, Mavrogeni, Sophie, additional, Aggeli, Constantina, additional, Psichogiou, Mina, additional, and Barbetseas, John, additional

Published
2022
Full Text
View/download PDF

49. Sexualized Drug Use and Chemsex: Their Association with Sexual Health Among Men who have Sex with Men Living in Greece

Author

Poulios, Antonios, primary, Apostolidou, Anna, additional, Triantafyllidou, Stavroula, additional, Protopapas, Konstantinos, additional, Tapeinos, Athanasios, additional, Papadopetrakis, Georgios, additional, Papadopoulou, Martha, additional, Antoniadou, Anastasia, additional, Psichogiou, Mina, additional, and Canellopoulos, Lissy, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results